ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan Sells 552 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating) COO Brendan Teehan sold 552 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $18.18, for a total value of $10,035.36. Following the completion of the sale, the chief operating officer now directly owns 3,437 shares in the company, valued at approximately $62,484.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brendan Teehan also recently made the following trade(s):

  • On Wednesday, February 23rd, Brendan Teehan sold 472 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $23.80, for a total value of $11,233.60.

Shares of ACADIA Pharmaceuticals stock opened at $19.81 on Wednesday. The firm has a 50-day moving average of $23.79 and a 200-day moving average of $22.62. ACADIA Pharmaceuticals Inc. has a 52-week low of $15.68 and a 52-week high of $28.06.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Rating) last issued its quarterly earnings data on Monday, February 28th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The business had revenue of $130.80 million during the quarter, compared to analyst estimates of $135.44 million. ACADIA Pharmaceuticals had a negative return on equity of 29.79% and a negative net margin of 34.67%. During the same quarter last year, the firm earned ($0.42) EPS. ACADIA Pharmaceuticals’s revenue for the quarter was up 8.1% compared to the same quarter last year. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post -1.32 earnings per share for the current year.

ACAD has been the topic of a number of analyst reports. Cantor Fitzgerald upped their price objective on ACADIA Pharmaceuticals from $32.00 to $37.00 and gave the stock an “overweight” rating in a research note on Thursday, March 10th. Canaccord Genuity Group upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $30.00 to $31.00 in a research note on Wednesday, March 16th. Mizuho decreased their price objective on shares of ACADIA Pharmaceuticals from $28.00 to $27.00 and set a “neutral” rating for the company in a research report on Tuesday, April 19th. Citigroup upped their target price on shares of ACADIA Pharmaceuticals from $30.00 to $32.00 in a report on Tuesday, March 1st. Finally, HC Wainwright upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $18.00 to $36.00 in a research note on Wednesday, February 9th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $29.41.

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in ACADIA Pharmaceuticals by 319.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,655 shares of the biopharmaceutical company’s stock worth $1,024,000 after acquiring an additional 46,947 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of ACADIA Pharmaceuticals by 8.7% during the 4th quarter. Russell Investments Group Ltd. now owns 138,950 shares of the biopharmaceutical company’s stock worth $3,241,000 after purchasing an additional 11,172 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in ACADIA Pharmaceuticals by 21.4% in the third quarter. Rockefeller Capital Management L.P. now owns 281,228 shares of the biopharmaceutical company’s stock valued at $4,671,000 after purchasing an additional 49,644 shares in the last quarter. First Quadrant L P CA lifted its position in ACADIA Pharmaceuticals by 37.5% during the fourth quarter. First Quadrant L P CA now owns 16,500 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 4,500 shares during the period. Finally, Balyasny Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals during the third quarter worth about $2,142,000. Institutional investors and hedge funds own 91.74% of the company’s stock.

About ACADIA Pharmaceuticals (Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Featured Stories

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.